Implantable Cardioverter-Defibrillator Therapy for Primary Prevention of Sudden Death After Alcohol Septal Ablation of Hypertrophic Cardiomyopathy

Journal of the American College of Cardiology

Volumn 52, Issue 21, 2008, Pages 1718-1723

  Cuoco, Frank A ^a   Spencer III, William H ^a   Fernandes, Valerian L ^a   Nielsen, Christopher D ^a   Nagueh, Sherif ^a   Sturdivant, J Lacy ^a   Leman, Robert B ^a   Wharton, J Marcus ^a   Gold, Michael R ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

alcohol septal ablation; hypertrophic cardiomyopathy; implantable cardioverter defibrillator; sudden cardiac death

Indexed keywords

ADULT; AGED; ALCOHOL SEPTAL ABLATION; ARTICLE; CARDIOVASCULAR PROCEDURES; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATOR; FEMALE; FOLLOW UP; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MYOMECTOMY; PRIMARY PREVENTION; PRIORITY JOURNAL; SUDDEN DEATH;

ADULT; AGED; CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; COMBINED MODALITY THERAPY; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ETHANOL; FEMALE; FOLLOW-UP STUDIES; HEART SEPTUM; HUMANS; INJECTIONS, INTRALESIONAL; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PRIMARY PREVENTION; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 55549112589     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.07.061     Document Type: Article

References (39)

1. Maron B.J., McKenna W.J., Danielson G.K., et al. ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Guidelines (Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathy). J Am Coll Cardiol 42 (2003) 1687-1713
2. Frank S., and Braunwald E. Idiopathic hypertrophic subaortic stenosis: clinical analysis of 126 patients with emphasis on the natural history. Circulation 37 (1968) 759-788
3. Maron B.J., Olivotto I., Spirito P., et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral based patient population. Circulation 102 (2000) 858-864
4. Spirito P., Seidman C.E., McKenna W.J., and Maron B.J. The management of hypertrophic cardiomyopathy. N Engl J Med 336 (1997) 775-785
5. Maron B.J. Hypertrophic cardiomyopathy. Lancet 350 (1997) 127-133
6. Maron B.J. Hypertrophic cardiomyopathy: a systematic review. JAMA 287 (2002) 1308-1320
7. Williams W.G., Wigle E.D., Rakowski H., Smallhorn J., LeBlanc J., and Trusler G.A. Results of surgery for hypertrophic obstructive cardiomyopathy. Circulation 76 (1987) V10-V18
8. Mohr R., Schaff H.V., Danielson G.K., Puga F.J., Pluth J.R., and Tajik A.J. The outcome of surgical treatment of hypertrophic obstructive cardiomyopathy: experience over 15 years. J Thorac Cardiovasc Surg 97 (1990) 666-674
9. Seiler C., Hess O.M., Schoenbeck M., et al. Long term follow-up of medical versus surgical therapy for hypertrophic cardiomyopathy: a retrospective study. J Am Coll Cardiol 17 (1991) 634-642
10. ten Berg J.M., Suttorp M.J., Knaepen P.J., Ernest S.M., Vermeulen F.E., and Jasarsma W. Hypertrophic obstructive cardiomyopathy: initial results and long term follow-up after Morrow septal myectomy. Circulation 90 (1994) 1781-1785
11. Heric B., Lytle B.W., Miller D.P., Rosenkranz E.R., Lever H.M., and Cosgrove D.M. Surgical management of hypertrophic obstructive cardiomyopathy: early and late results. J Thorac Cardiovasc Surg 110 (1995) 195-206
12. Ommen S.R., Maron B.J., Olivotto I., et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 46 (2005) 470-476
13. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346 (1995) 211-214
14. Knight C., Kurbasan A.S., Seggewiss H., et al. Non-surgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 95 (1997) 2075-2081
15. Seggewiss H., Gleichmann U., Faber L., Fassbender D., Schmidt H., and Strick S. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 31 (1998) 252-258
16. Lakkis N.M., Nagueh S.F., Kleiman N.S., et al. Echocardiography guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 98 (1998) 1750-1755
17. Nagueh S.F., Ommen S.R., Lakkis N.M., et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38 (2001) 1701-1706
18. Lakkis N.M., Nagueh S.F., Dunn J.K., et al. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. J Am Coll Cardiol 36 (2000) 852-855
19. Maron B.J. Role of alcohol septal ablation in the treatment of obstructive hypertrophic cardiomyopathy. Lancet 355 (2000) 425-426
20. Mazur W., Nagueh S.F., Lakkis N.M., et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 103 (2001) 1492-1496
21. Gietzen F.H., Leuner C.J., Raute-Kreinsen U., et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH): catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 20 (1999) 1342-1354
22. Lawrenz T., Obergassel L., Lieder F., et al. Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy. Pacing Clin Electrophysiol 28 (2005) 295-300
23. Kazmierczak J., Kornacewicz-Jach Z., Kisly M., et al. Electrocardiographic changes after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Heart 80 (1998) 257-262
24. McGregor J.B., Rahman A., Rosanio S., et al. Monomorphic ventricular tachycardia: a late complication of percutaneous alcohol septal ablation for hypertrophic cardiomyopathy. Am J Med Sci 328 (2004) 185-188
25. Boltwood C.M., and Chien W. Ventricular tachycardia complicating alcohol septal ablation. N Engl J Med 351 (2004) 1914-1915
26. Simon R.D.B., Crawford F.A., Spencer W.H., and Gold M.R. Sustained ventricular tachycardia following alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Pacing Clin Electrophysiol 28 (2005) 1354-1356
27. Maron B.J., Spirito P., Shen W.K., et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 298 (2007) 405-412
28. Maron B.J., Shen W.-K., Link M.S., et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 342 (2000) 365-373
29. Adabag A.S., Casey S.A., Kuskowski M.A., et al. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol 45 (2005) 697-704
30. Maron B.J., Bonow R.O., Cannon R.O., Leon M.B., and Epstein S.E. Hypertrophic cardiomyopathy: interrelation of clinical manifestations, pathophysiology, and therapy. N Engl J Med 316 (1987) 780-789 844-52
31. Maron B.J. Hypertrophic cardiomyopathy and sudden death: new perspectives on risk stratification and prevention with the implantable cardioverter-defibrillator. Eur Heart J 21 (2000) 1979-1983
32. Elliot P.M., Gimeno J.R., Tome M.T., et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 27 (2006) 1933-1941
33. van Dockum W.G., ten Cate F.J., ten Berg J.M., et al. Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging. J Am Coll Cardiol 43 (2004) 27-34
34. Gradel C., Jain D., Batsford W.P., et al. Relationship of scar and ischemia to the results of programmed electrophysiological stimulation in patients with coronary artery disease. J Nucl Cardiol 4 (1997) 379-386
35. Spirito P., Bellone P., Harris K.M., et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 342 (2000) 1778-1785
36. Fernandes V.L., Nagueh S.F., Franklin J., et al. A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy-the Baylor experience (1996-2002). Clin Cardiol 28 (2005) 124-130
37. Chang S.M., Lakkis N.M., Franklin J., et al. Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation 109 (2004) 824-827
38. McLeod C.J., Ommen S.R., Ackerman M.J., et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Hear J 28 (2007) 2583-2588
39. Maron M.S., Olivotto I., Betocchi S., et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348 (2003) 295-303